InMed shares rise 15.0% premarket after shareholder approval of 20% SEPA issuance and director elections.

InMed Pharmaceuticals (NASDAQ: INM) surged 15.0% in premarket trading following the announcement of favorable shareholder meeting results. At its 2025 annual general and special meeting on December 17, 2025, shareholders approved key corporate governance and financial measures, including the re-election of five directors with ~82% support, the appointment of CBIZ CPAs as auditors, and the potential issuance of up to 20% of outstanding shares under the amended Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. These approvals signaled strong investor confidence in management’s strategic direction and capital-raising flexibility, particularly the SEPA authorization, which provides a financial lifeline for pipeline development. The positive outcome aligned with the company’s focus on advancing Alzheimer’s, ocular, and dermatological therapies, reinforcing market optimism ahead of clinical milestones and regulatory progress.